Table 3.
Fluorescein angiography findings among the treated and untreated cohorts between 1st December 2013 and 31st July 2018
| No. (%) | |||
|---|---|---|---|
| Findings | Anti-VEGF cohort (40 eyes) |
Untreated cohort (16 eyes) |
p-value |
| Neovascularization | 12 (30.0) | 6 (37.5) | 0.75 |
| Occult neovascularization | 5 (12.5) | 5 (31.3) | 0.12 |
| Peripheral findings | |||
| Anomalous branching pattern | 40 (100.0) | 16 (100.0) | - |
| Blunting | 38 (95.0) | 14 (87.5) | 0.56 |
| Double blunting | 3 (7.5) | 0 (0.0) | 0.54 |
| Abnormal capillary bed | 12 (30.0) | 5 (31.3) | 1 |
| Vascular shunt | 34 (85.0) | 10 (62.5) | 0.08 |
| Shunt crossing horizontal raphe | 11 (27.5) | 1 (6.3) | 0.08 |
| Shunt at junction | 2 (5.0) | 4 (25.0) | 0.05 |
| Posterior pole findings | |||
| Vessel encroaching onto fovea | 26 (65.0) | 4 (25.0) | 0.009 |
| Vessel crossing fovea | 5 (12.5) | 1 (6.3) | 0.66 |
| Tortuosity | 7 (17.5) | 5 (31.3) | 0.29 |